New Frontier Labs LLC, San Antonio, TX, U.S.A.
In Vivo. 2022 Jan-Feb;36(1):86-93. doi: 10.21873/invivo.12679.
BACKGROUND/AIM: Brown recluse spider bite releases hemolytic and cytotoxic phospholipase D to the wound that may cause necrosis or even death. We examined diethyl azelate (DEA), a plasma membrane fluidizer with a broad range of immunomodulatory activities, as a potential treatment for the brown recluse spider bite.
Topical DEA was used in emergency to treat brown recluse spider bites in a human subject. We subsequently evaluated the effects of DEA on hemolysis induced by the brown recluse spider venom, recluse recombinant phospholipase D (rPLD), and venoms from honey bee and moccasin snake, and on phospholipase A2 activity in the bee and snake venoms and in human urine.
Topical DEA resolved the consequences of human brown recluse spider envenomation in two weeks. In vitro, DEA inhibited hemolysis caused by the brown recluse spider venom and rPLD and suppressed phospholipase A2 activity in a dose-dependent manner.
DEA is a promising novel therapy for the brown recluse spider bite and perhaps even unrelated envenomations involving PLDs.
背景/目的:褐隐士蜘蛛咬伤会向伤口释放溶血性和细胞毒性的磷脂酶 D,可能导致坏死甚至死亡。我们研究了二乙基己酸酯(DEA),一种具有广泛免疫调节活性的质膜流动性调节剂,作为治疗褐隐士蜘蛛咬伤的潜在药物。
在紧急情况下,局部使用 DEA 治疗人类褐隐士蜘蛛咬伤。随后,我们评估了 DEA 对褐隐士蜘蛛毒液、隐士重组磷脂酶 D(rPLD)、蜜蜂和响尾蛇毒液引起的溶血以及对蜜蜂和响尾蛇毒液以及人尿中 PLA2 活性的影响。
局部 DEA 在两周内解决了人类褐隐士蜘蛛中毒的后果。体外,DEA 以剂量依赖的方式抑制褐隐士蜘蛛毒液和 rPLD 引起的溶血,并抑制 PLA2 活性。
DEA 是治疗褐隐士蜘蛛咬伤的一种很有前途的新型疗法,甚至可能对涉及 PLD 的其他无关咬伤也有疗效。